262 related articles for article (PubMed ID: 29175180)
1. Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP.
Järvinen E; Deng F; Kidron H; Finel M
J Steroid Biochem Mol Biol; 2018 Apr; 178():99-107. PubMed ID: 29175180
[TBL] [Abstract][Full Text] [Related]
2. Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
Järvinen E; Troberg J; Kidron H; Finel M
Mol Pharm; 2017 Oct; 14(10):3299-3311. PubMed ID: 28850245
[TBL] [Abstract][Full Text] [Related]
3. Human efflux transport of testosterone, epitestosterone and other androgen glucuronides.
Järvinen E; Kidron H; Finel M
J Steroid Biochem Mol Biol; 2020 Mar; 197():105518. PubMed ID: 31704245
[TBL] [Abstract][Full Text] [Related]
4. Major glucuronide metabolites of testosterone are primarily transported by MRP2 and MRP3 in human liver, intestine and kidney.
Li CY; Basit A; Gupta A; Gáborik Z; Kis E; Prasad B
J Steroid Biochem Mol Biol; 2019 Jul; 191():105350. PubMed ID: 30959153
[TBL] [Abstract][Full Text] [Related]
5. Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters.
Järvinen E; Sjöstedt N; Koenderink JB; Kidron H; Finel M
Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):490-498. PubMed ID: 31237077
[TBL] [Abstract][Full Text] [Related]
6. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
[TBL] [Abstract][Full Text] [Related]
7. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
8. The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells.
Li S; Xu J; Yao Z; Hu L; Qin Z; Gao H; Krausz KW; Gonzalez FJ; Yao X
Chem Biol Interact; 2018 Dec; 296():45-56. PubMed ID: 30237061
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
Imai Y; Asada S; Tsukahara S; Ishikawa E; Tsuruo T; Sugimoto Y
Mol Pharmacol; 2003 Sep; 64(3):610-8. PubMed ID: 12920197
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
[TBL] [Abstract][Full Text] [Related]
11. Efflux excretion of bisdemethoxycurcumin-O-glucuronide in UGT1A1-overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 (MRP1) as the glucuronide transporters.
Yang J; Zhang B; Qin Z; Li S; Xu J; Yao Z; Zhang X; Gonzalez FJ; Yao X
Biofactors; 2018 Nov; 44(6):558-569. PubMed ID: 30334318
[TBL] [Abstract][Full Text] [Related]
12. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
13. Characterization of chrysin glucuronidation in UGT1A1-overexpressing HeLa cells: elucidating the transporters responsible for efflux of glucuronide.
Quan E; Wang H; Dong D; Zhang X; Wu B
Drug Metab Dispos; 2015 Apr; 43(4):433-43. PubMed ID: 25595598
[TBL] [Abstract][Full Text] [Related]
14. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells.
Brand W; Oosterhuis B; Krajcsi P; Barron D; Dionisi F; van Bladeren PJ; Rietjens IM; Williamson G
Biopharm Drug Dispos; 2011 Dec; 32(9):530-5. PubMed ID: 22083890
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions.
Bodo A; Bakos E; Szeri F; Varadi A; Sarkadi B
J Biol Chem; 2003 Jun; 278(26):23529-37. PubMed ID: 12704183
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro conjugation and metabolism of estrogens by the baboon kidney.
Honjo H; Ishihara M; Osawa Y; Kirdani RY; Sandberg AA
Endocrinology; 1976 Oct; 99(4):1054-62. PubMed ID: 824121
[TBL] [Abstract][Full Text] [Related]
18. Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.
Koenderink JB; van den Heuvel JJMW; Bilos A; Vredenburg G; Vermeulen NPE; Russel FGM
Arch Toxicol; 2020 Sep; 94(9):3027-3032. PubMed ID: 32472168
[TBL] [Abstract][Full Text] [Related]
19. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.
Jiang W; Xu B; Wu B; Yu R; Hu M
Drug Metab Dispos; 2012 Feb; 40(2):336-45. PubMed ID: 22071170
[TBL] [Abstract][Full Text] [Related]
20. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
